Cabozantinib, SELPERCATINIB, VANDETANIB, SELPERCATINIB, Cabozantinib, CABOZANTINIB
J2G-MC-JZJB
Phase 3 small_molecule active
Quick answer
Cabozantinib, SELPERCATINIB, VANDETANIB, SELPERCATINIB, Cabozantinib, CABOZANTINIB for RET-Mutant Medullary Thyroid Cancer is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- RET-Mutant Medullary Thyroid Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active